Lucid Diagnostics Announces $15.3M Registered Direct Offering Of 13,939,331 Shares Of Common Stock At A Purchase Price Of $1.10 Per Share

Author: Benzinga Newsdesk | March 04, 2025 09:26am

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company.

Canaccord Genuity is acting as the sole placement agent for this offering.

Posted In: LUCD PAVM